UNSPSC 51452004: Nitramisole

This classification denotes an antihelminthic agent with the molecular formula C11H11N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 770KB1W9T8, chemically known as imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-(3-nitrophenyl)-, which bears US NIH Compound Identifier 163306. Most nations schedule nitramisole under HS 29349990 and SITC 51579. As of Q4 2014, NITRAMISOLE remains the US FDA Preferred Term for this commodity. Nitramisole bears US NLM identifiers UMLS ID C0068797 and NCI Concept Code C95056.

SMILES: C1CSC2=NC(CN21)C3=CC(=CC=C3)[N+](=O)[O-].

UNSPSC 51452004 Nitramisole is a Commodity code that captures pharmaceutical products and medical supplies procured by state and local health agencies, emergency response departments, and cooperative purchasing alliances. Recent solicitations show state and local buyers are actively acquiring naloxone and drug deactivation systems for community health initiatives, medical and first aid supplies for emergency response operations, and generic pharmaceuticals and over-the-counter products through statewide cooperative purchasing vehicles. The code encompasses both specialized emergency-response medications and broader pharmaceutical supply categories distributed across multiple jurisdictions and facilities.

Issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Recent activity spans Florida, Texas, and Minnesota through MMCAP's multi-state vehicle serving state and local facilities in participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023); the City of Tampa's sealed-bid solicitation for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract amount of $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount (26P00145, due March 13, 2026); the Texas Health and Human Services Commission's Request for Information regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program (HHS0017013, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities (S1070000015802, due March 26, 2026).